Resistance studies of a dithiazol analogue, dbpr110, as a potential hepatitis c virus NS5A inhibitor in replicon systems

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 723-733

  Lin, Hui Mei ^a   Wang, Jing Chyi ^b   Hu, Han Shu ^a   Wu, Pei Shan ^b   Wang, Wen Hung ^a   Wu, Su Ying ^a   Yang, Chi Chen ^a   Yeh, Teng Kuang ^a   Hsu, Tsu An ^a   Jiaang, Weir Torn ^a,b   Chao, Yu Sheng ^a   Chern, Jyh Haur ^a,b   Yueha, Andrew ^b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DBPR 110; NONSTRUCTURAL PROTEIN 5A; THIAZOLE; UNCLASSIFIED DRUG; VIRUS RNA;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; REPLICON; VIRUS INHIBITION; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MUTATION; PROTEIN BINDING; PYRROLIDINES; REPLICON; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84872836019     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01403-12     Document Type: Article

References (58)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115.
2. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-S29.
3. Foster G, Mathurin P. 2008. Hepatitis C virus therapy to date. Antivir. Ther. 13(Suppl 1):3-8.
4. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. 2007. The way forward inHCVtreatment-finding the right path. Nat. Rev. Drug Discov. 6:991-1000.
5. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R. 2008. Essential role of domain III of nonstructural protein 5A for hepatitisCvirus infectious particle assembly. PLoS Pathog. 4:e1000035. doi:10.1371/journal.ppat.1000035.
6. Jirasko V, Montserret R, Appel N, Janvier A, Eustachi L, Brohm C, Steinmann E, Pietschmann T, Penin F, Bartenschlager R. 2008. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J. Biol. Chem. 283:28546-28562.
7. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 81:8374-8383.
8. Ma Y, Yates J, Liang Y, Lemon SM, Yi M. 2008. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J. Virol. 82:7624-7639.
9. Beran RK, Serebrov V, Pyle AM. 2007. The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J. Biol. Chem. 282:34913-34920.
10. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3= nontranslated region are essential for virus replication in vivo. J. Virol. 74:2046-2051.
11. Lam AM, Frick DN. 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol. 80:404-411.
12. Pang PS, Jankowsky E, Planet PJ, Pyle AM. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 21:1168-1176.
13. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. 2004. Structural biology of hepatitis C virus. Hepatology 39:5-19.
14. Einav S, Elazar M, Danieli T, Glenn JS. 2004. A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. J. Virol. 78:11288-11295.
15. Elazar M, Liu P, Rice CM, Glenn JS. 2004. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J. Virol. 78:11393-11400.
16. Evans MJ, Rice CM, Goff SP. 2004. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viralRNA replication. Proc. Natl. Acad. Sci. U. S. A. 101:13038-13043.
17. Tellinghuisen TL, Foss KL, Treadaway J. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4:e1000032. doi:10.1371/journal.ppat.1000032.
18. He Y, Staschke KA, Tan SL. 2006. HCV NS5A: A multifunctional regulator of cellular pathways and virus replication, p 267-292. In Tan SL (ed), Hepatitis C viruses: Genomes and molecular biology. Horizon Bioscience, Norfolk, United Kingdom.
19. Huang Y, Staschke K, De Francesco R, Tan SL. 2007. Phosphorylation of hepatitisCvirus NS5A nonstructural protein: A new paradigm for phosphorylation-dependent viral RNA replication? Virology 364:1-9.
20. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379.
21. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395-4403.
22. Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS. 2003.Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J. Virol. 77:6055-6061.
23. Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, Blum HE, Bartenschlager R, Moradpour D. 2004. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 279:40835-40843.
24. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. 2004. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279:48576-48587.
25. Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, Brain P, Tran TD, Jones LH, Wakenhut F, Stammen B, Pryde D, Pickford C, Westby M. 2011. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action. J. Virol. 85:6353-6368.
26. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100.
27. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. 2012. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J. Hepatol. 57:24-31.
28. Koch U, Narjes F. 2006. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect. Disord. Drug Targets 6:31-41.
29. Moradpour D, Brass V, Bieck E, Friebe P, Gosert R, Blum HE, Bartenschlager R, Penin F, Lohmann V. 2004. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J. Virol. 78:13278-13284.
30. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
31. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449.
32. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
33. Kwong AD, McNair L, Jacobson I, George S. 2008. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8:522-531.
34. Legrand-Abravanel F, Nicot F, Izopet J. 2010. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Investig. Drugs 19:963-975.
35. Naggie S, Patel K, McHutchison J. 2010. Hepatitis C virus directly acting antivirals: Current developments with NS3/4AHCVserine protease inhibitors. J. Antimicrob. Chemother. 65:2063-2069.
36. Kwo PY, Zhao R. 2011. Boceprevir: A user's guide. Clin. Liver Dis. 15: 537-553.
37. Liapakis A, Jacobson I. 2011. Telaprevir user's guide. Clin. Liver Dis. 15:555-571.
38. Lemm JA, O'Boyle D, 2nd, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M. 2010. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84:482-491.
39. Lin HM, Wang JC, Hu HS, Wu PS, Yang CC, Wu CP, Pu SY, Hsu TA, Jiaang WT, Chao YS, Chern JH, Yeh TK, Yueh A. 2012. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor. Antimicrob. Agents Chemother. 56:44-53.
40. Miroux B, Walker JE. 1996. Over-production of proteins in Escherichia coli: Mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260:289-298.
41. Burke D. 2000. Methods in yeast genetics: A Cold Spring Harbor Laboratory course manual. Cold Spring Harbor Laboratory Press, Plainview, NY.
42. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA. 2003. Characterization of resistance to non-obligate chainterminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
43. Lin K, Perni RB, Kwong AD, Lin C. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50:1813-1822.
44. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
45. Zhang Y, Weady P, Duggal R, Hao W. 2008. Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. Antimicrob. Agents Chemother. 52:666-674.
46. Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, Moulton HM, Iversen PL, Kauffman EB, Kramer LD, Shi PY. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609.
47. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
48. Zou G, Puig-Basagoiti F, Zhang B, Qing M, Chen L, Pankiewicz KW, Felczak K, Yuan Z, Shi PY. 2009. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384:242-252.
49. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
50. Tallarida RJ. 2002. The interaction index: A measure of drug synergism. Pain 98:163-168.
51. Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE, Goebel SJ, Masters PS, Falgout B, Ren P, Ferguson DM, Shi PY. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320-1329.
52. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F. 2007. Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. World J. Gastroenterol. 13:2416-2426.
53. Thompson AJ, McHutchison JG. 2009. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J. Viral Hepat. 16:377-387.
54. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
55. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G. 2007. euHCVdb: The European hepatitis C virus database. Nucleic Acids Res. 35:D363-D366.
56. Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar M, Klumpp K, Glenn JS. 2011. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414:10-18.
57. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. 2011. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:7312-7320.
58. Buckwold VE. 2004. Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus. J. Antimicrob. Chemother. 53:413-414.